MEDI 4276

Drug Profile

MEDI 4276

Alternative Names: MEDI4276

Latest Information Update: 01 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MedImmune
  • Class Antineoplastics; Bispecific antibodies; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action ERBB 2 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Gastric cancer

Most Recent Events

  • 01 Aug 2018 Discontinued - Phase-I for Breast cancer (Late-stage disease, Second-line therapy or greater, In adults) in USA (PO) (AstraZeneca pipeline, July 2018)
  • 01 Aug 2018 Discontinued - Phase-I for Gastric cancer (Late-stage disease, Second-line therapy or greater, In adults) in USA (PO) (AstraZeneca pipeline, July 2018)
  • 05 Mar 2018 Adverse events, efficacy and pharmacokinetics data from a phase I trial in Cancer presented at the 16th International Congress on Targeted Anticancer Therapies (TAT-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top